Get started
Work

Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial

Year: 2017
Type: article
Source: Diabetologia
DOI: 10.1007/s00125-017-4485-y
Authors: Jelena P. Seferovic, Marc A. Pfeffer, Brian Claggett, Akshay S. Desai, Dick de Zeeuw, Steven M. Haffner, John J. V. McMurray, Hans-Henrik Parving, Scott D. Solomon, Nish Chaturvedi
Institutions: Brigham and Women's Hospital, Harvard University, University Medical Center Groningen, University of Groningen, The University of Texas at San Antonio Health Science Center, University of Glasgow, University of Copenhagen, Aarhus University, Rigshospitalet, University College London
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Brigham and Women's Hospital, Gilead Sciences, Teva Pharmaceutical Industries, Celladon Corporation, Steno Diabetes Center Copenhagen, Kidney Research UK, University of Oxford, University of Glasgow, Novo Nordisk, Astellas Pharma, Universitair Medisch Centrum Groningen, European Association for the Study of Diabetes, Relypsa
OpenAlex ID: W2766472741
FWCI: 1.713
Cites: 21
Cited by: 20
Related to: 10